These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21820182)

  • 41. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder.
    Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS
    Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Duloxetine: a review of its use in the management of major depressive disorder in older adults.
    Dhillon S
    Drugs Aging; 2013 Jan; 30(1):59-79. PubMed ID: 23239363
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High baseline BDNF serum levels and early psychopathological improvement are predictive of treatment outcome in major depression.
    Mikoteit T; Beck J; Eckert A; Hemmeter U; Brand S; Bischof R; Holsboer-Trachsler E; Delini-Stula A
    Psychopharmacology (Berl); 2014 Aug; 231(15):2955-65. PubMed ID: 24562062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD).
    Baldwin DS; Loft H; Dragheim M
    Eur Neuropsychopharmacol; 2012 Jul; 22(7):482-91. PubMed ID: 22209361
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Duloxetine-bupropion combination for treatment-resistant atypical depression: a double-blind, randomized, placebo-controlled trial.
    Fornaro M; Martino M; Mattei C; Prestia D; Vinciguerra V; De Berardis D; De Pasquale C; Iasevoli F; Mungo S; Fornaro P
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1269-78. PubMed ID: 24842649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder.
    Raskin J; Xu JY; Kajdasz DK
    Int Psychogeriatr; 2008 Apr; 20(2):309-27. PubMed ID: 17588276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Duloxetine-related growth of putamen and brainstem in first-onset drug-naive major depressive disorder with panic disorder: a case series.
    Lai CH
    J Neuropsychiatry Clin Neurosci; 2011; 23(2):E40-1. PubMed ID: 21677224
    [No Abstract]   [Full Text] [Related]  

  • 49. Effects of baseline depression severity on remission rates with duloxetine and placebo in anxious and nonanxious patients with major depression.
    Nelson JC
    J Clin Psychopharmacol; 2011 Oct; 31(5):682-4. PubMed ID: 21881463
    [No Abstract]   [Full Text] [Related]  

  • 50. Preclinical discovery of duloxetine for the treatment of depression.
    Torres-Sanchez S; Perez-Caballero L; Mico JA; Elorza J; Berrocoso E
    Expert Opin Drug Discov; 2012 Aug; 7(8):745-55. PubMed ID: 22680253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reduced serum VGF levels were reversed by antidepressant treatment in depressed patients.
    Jiang H; Chen S; Lu N; Yue Y; Yin Y; Zhang Y; Jiang W; Liang J; Yuan Y
    World J Biol Psychiatry; 2017 Dec; 18(8):586-591. PubMed ID: 28635540
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and demographic predictors of improvement during duloxetine treatment in patients with major depression: an open-label study.
    Nasso ED; Chiesa A; Serretti A; De Ronchi D; Mencacci C
    Clin Drug Investig; 2011; 31(6):385-405. PubMed ID: 21366360
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Duloxetine.
    Preskorn SH
    J Psychiatr Pract; 2004 Nov; 10(6):375-85. PubMed ID: 15583519
    [No Abstract]   [Full Text] [Related]  

  • 56. Frontal regional homogeneity increased and temporal regional homogeneity decreased after remission of first-episode drug-naïve major depressive disorder with panic disorder patients under duloxetine therapy for 6 weeks.
    Lai CH; Wu YT
    J Affect Disord; 2012 Feb; 136(3):453-8. PubMed ID: 22137181
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder.
    López-Solà M; Pujol J; Hernández-Ribas R; Harrison BJ; Contreras-Rodríguez O; Soriano-Mas C; Deus J; Ortiz H; Menchón JM; Vallejo J; Cardoner N
    Neuropsychopharmacology; 2010 Oct; 35(11):2305-17. PubMed ID: 20668437
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Markers of mineralocorticoid receptor function: changes over time and relationship to response in patients with major depression.
    Murck H; Braunisch MC; Konrad C; Jezova D; Kircher T
    Int Clin Psychopharmacol; 2019 Jan; 34(1):18-26. PubMed ID: 30300165
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Somatic symptoms, depression, and antidepressant treatment.
    Fava M
    J Clin Psychiatry; 2002 Apr; 63(4):305-7. PubMed ID: 12000203
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of antidepressants on melatonin metabolite in depressed patients.
    Carvalho LA; Gorenstein C; Moreno R; Pariante C; Markus RP
    J Psychopharmacol; 2009 May; 23(3):315-21. PubMed ID: 18562432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.